Other

Lts Lohmann Therapie-Systeme Ag

Lts Lohmann Therapie-Systeme Gmbh + Co. Kg

Hf Arzneimittelforschung Gmbh

Hefa-Frenon Arzneimittel Gmbh & Co. Kg

Klaus Opitz

Thomas Hille

Hans-Rainer Hoffmann

Bodo Asmussen

Frank Becher

Joachim Moormann

Hermann Mucke

The invention relates to the use of galanthamine, as free base or as acid addition salt, for the treatment of cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders occurring through intake of psychotropic substances as a consequence of occasional or chronic abuse of addictive substances, intoxicants or medicines, or as side effects of the use, especially repeated or prolonged, as intended of medicaments, or as an effect of use, in particular repeated or prolonged, not as intended of medicaments, or as a result of acute poisoning by psychotropic toxic substances, or as a result of chronic exposure to toxic substances with a psychotropic effect in humans or other vertebrates.

Use of galanthamine for the treatment of pathological manifestations of the central nervous system based on intoxications with psychotropic substances

Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuos and controlled manner. The pharmaceutical administration form enables controlled release, e.g. for oral, transdermal or another route of parenteral administration.

Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism

Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of drug addiction or drug dependence. Said substances are administered preferably in a continuos and controlled manner. The pharmaceutical administration form enables controlled release, e.g. for oral transdermal or another route of parenteral administration.

Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence

Desoxypeganine and its pharmaceutically acceptable acid addition salts are useful in treating nicotine dependence.

Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence

The invention relates to a device and method for the treatment of Alzheimer's dementia with desoxypeganine and/or a pharmaceutically acceptable acid addition salt of desoxypeganine.

Use of desoxypeganine in the treatment of Alzheimer's dementia

Galanthamine and the pharmaceutically suitable acid addition salts thereof can be used for the treatment of alcoholism; these compounds are released from adequate pharmaceutic formulations which are administered, e.g., orally, transdermally, or otherwise parenterally, in a continuous and controlled manner.

Growing community of inventors

Münster, Germany

Klaus Opitz